Sorafenib was postulated to inhibit the TGF-mediated EMT possibly via inhibition of TGF-β and MAPK signalling, and SNAI1 expression in HCC, thus inducing antitumour effects [83, 90]. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.